Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the clinical improvement (change in seizure frequency), safety and tolerability of patients with partial seizures following adjunctive therapy of pregabalin BID in addition to existing standard AEDs.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Male and female subjects with a diagnosis of partial epilepsy.

• 18 years and older.

Exclusion Criteria:

• Having a treatable cause of seizure.

• Having a progressive neurological or systemic disorder